Basal cell carcinoma

7 trials 4 recruiting MedDRA PT
7 Registered trials
4 Recruiting
6 Unique sponsors
4 Unique IMPs
5 Commercial trials
Drug classes (ATC)
— ATC code not specified 5
D Dermatology (ATC D) 1
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 3 substances
Macrolide / aminoglycoside 1 substance
Phase II/III: 1 Phase II: 2 Phase IV: 1 Phase I: 3

Filter these 7 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 7 trials

Phase II/III

1 trial
  • Centre Hospitalier Universitaire De Nantes Academic
    TIRBANIBULIN
    2023-505971-66-00 1 country 2023 n=55
    Recruiting

Phase II

2 trials
  • Philogen S.p.A. Commercial
    BIFIKAFUSP ALFA; ONFEKAFUSP ALFA
    2024-518530-92-00 2 countries 2024 n=78
    Ended
  • Philogen S.p.A. Commercial
    BIFIKAFUSP ALFA; ONFEKAFUSP ALFA
    2025-523229-16-00 4 countries 2026 n=85
    Recruiting

Phase IV

1 trial
  • Region Hovedstaden Academic
    BLEOMYCIN
    2024-519066-49-01 1 country 2020 n=52
    Recruiting

Phase I

3 trials
  • Celgene Corp. Commercial
    IMP not specified
    2023-509969-20-00 2 countries 2017 n=127
    Ended
  • Kupando GmbH Commercial
    IMP not specified
    2025-522402-21-00 1 country 2026 n=21
    Recruiting
  • Regeneron Pharmaceuticals Inc. Commercial
    IMP not specified
    2024-511440-76-00 1 country 2025 n=5
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Philogen S.p.A. Commercial 2 Phase II 1
Celgene Corp. Commercial 1 Phase I 0
Kupando GmbH Commercial 1 Phase I 1
Regeneron Pharmaceuticals Inc. Commercial 1 Phase I 0
Centre Hospitalier Universitaire De Nantes Academic 1 Phase II/III 1
Region Hovedstaden Academic 1 Phase IV 1
New trials by year
2020
1
2023
1
2024
1
2025
1
2026
2
← All indication landscapes